Detail of 2581 - Moderate to Severe Atopic Dermatitis

2581 - Moderate to Severe Atopic Dermatitis ( active )

2581 - Moderate to Severe Atopic Dermatitis
  • Vertical:
  • 2581 - Moderate to Severe Atopic Dermatitis
  • Countries:
  • Traffic Types:
  • ------
  • Price Format:
  • cpa ( Base ) , cpa ( Referral Queue )

    Live Geos: https://partners.subjectwell.com/publishers/geos_report/9d319ff5-99be-4d47-b1db-59ee2b8cb95a Ages: 18+ Gender: All Study Description: The purpose of this clinical study is to assess the immune response to 2 different approved vaccines after receiving an investigational injectable medication for Atopic Dermatitis. You may be asked to attend 1 screening visit to determine if you are eligible to enroll in the study. If enrolled, you will receive 4 doses of either the injectable medication being tested or its placebo over the course of the study. You will also be given 2 vaccinations after you receive all doses of the investigational medication, and you will have your blood drawn to measure your immune response. Your total participation will last approximately 9 months and you will be asked to attend 7 doctor’s visits. During these visits, you will complete various diagnostic and laboratory tests. You may receive a stipend for travel and transportation. After this clinical study, you will be offered to enter into a long-term extension study where you will receive the investigational medication. The doctor’s office conducting the study will be able to provide you with more information about the study requirements. - Diagnosed for 1 year or more - Must cover >10% of your body - Have not had *certain* vaccines over the last 5 years